KRAS and neoplasm: RASON-KO inhibited KRAS downstream signaling (Fig. 4A), reduced in vitro proliferation (Fig. 4B) and suppressed in vivo tumor growth (Fig. 4C-G and Fig. S6A-D) in all three models.